TEST:

GenesWell BCT

A cost-effectiveness evaluation comparing the widely used ODX with BCT revealed that BCT is the dominant option in South Korea.

Furthermore, in the low-risk group according to Oncotype DX Recurrence Score, patients classified high risk by BCT Score and/or BCT Gene Score showed poor prognosis compared to other patients. Conclusions These results suggest that the addition of the BCT Gene Score to the BCT Score of GenesWell BCT allows for more accurate prediction of prognosis in patients with early breast cancer.

Patients receive palbociclib 125mg once daily for 21 days of 28-day cycle plus tamoxifen or aromatase inhibitor (anastrozole, letrozole or exemestane) once daily for every day. Significance level is 0.025, power is 0.80. Considering 10% drop out rate, 4-years of accrual patient enrollment and 3-years of follow up period, 578 patients were required in this clinical trial.

"The results of the Korea-Japan joint clinical study announced at GBCC last April were published in a paper...This study succeeded in demonstrating the excellent performance of Geneswell BCT not only in Korea but also in Japanese patients, and showed that the prognosis prediction period is possible up to 15 years."

"Gencurix's breast cancer prognostic diagnosis 'Ginswell BCT' has applied to 4 new hospitals. Including this new hospital, a total of 54 medical institutions nationwide will provide GenesWell BCT services...The number of hospitals adopting Geneswell BCT has been steadily increasing since prescriptions for general medical treatment became possible in mid-April."

The BCT score can identify patients at low risk for recurrence who may not require adjuvant chemotherapy or extended endocrine therapy, regardless of age.

"Gencurix...announced...that the Korea Health and Medical Research Institute (NECA) has additionally approved hospitals to introduce the 'Ginswell BCT' test service for breast cancer...As Geneswell BCT became available for prescription for general medical purposes in mid-April, more hospitals are introducing it."

"Gencurix announced on the 5th that six hospitals in Korea have newly applied for the introduction of 'Ginswell BCT'...a prognostic diagnosis service for breast cancer...Gencurix will provide Geneswell BCT service at a total of 50 medical institutions nationwide, including six newly introduced locations. According to Gencurex, Geneswell BCT has been available for prescription for general medical purposes since last April, and more hospitals are introducing it."

"Gencurix...announced the release of clinical research results directly comparing the accuracy of its breast cancer prognostic test, GenesWell BCT, with Oncotype DX, the globally top-selling test, confirming its outstanding performance....The results revealed that GenesWell BCT demonstrated a superior prognostic performance in accurately distinguishing high-risk and low-risk groups, with a Hazard Ratio of 2.469 for high-risk recurrence compared to 2.093 for OncotypeDX. This difference in favor of GenesWell BCT was even more pronounced in subgroup analyses based on lymph node metastasis."

"Gencurix announced...that 11 organizations applied for the use of Geneswell BCT to the Korea Health and Medical Research Institute (NECA) at the end of March and received final approval. The Korea Health and Medical Research Institute is an institution under the Ministry of Health and Welfare, and manages innovative medical technology implementation institutions."

"Gencurix...announced...that it would present the results of prognostic diagnosis clinical trials conducted on 366 Korean and Japanese breast cancer patients at the World Breast Cancer Conference (GBCC) to be held in Seoul...Gencurix's 'Ginswell BCT' was used to predict the prognosis of breast cancer...83.6% were classified as low-risk and 16.4% as high-risk. Clinical results showed that patients in the low-risk group had a significantly higher survival rate after surgery than those in the high-risk group."

We found that the BCT score was useful in stratifying the risk of relapse in chemotherapy-untreated patients with a low recurrence score (RS). This indicates that the BCT score could provide additional clinical value in identifying patients with a long-term risk of relapse, particularly in young women with an RS of 21 to 25.